An interventional study of Health Belief Model-based screening promotion intervention and Usual Care in Gastric Cancer (GC), sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in China. Open to participants aged 45 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Stomach Neoplasms by Chinese University of Hong Kong — 10 open to participants now, 10 under way, 1 of them phase 3. Stomach Neoplasms · Chinese University of Hong Kong.
Among the 18 studies in Stomach Neoplasms by Chinese University of Hong Kong, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 18th registered.
3,406 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.
Browse Stomach Neoplasms studies →10 of the 18 studies in Stomach Neoplasms by Chinese University of Hong Kong are open now, in 5 countries. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in Hong Kong, Japan
Ages 18–75
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–85
Chinese University of Hong Kong · Sites in China
Ages 18–80
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–80
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.
This study: 45 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 66 across 2,503 interventional studies indexed under Stomach Neoplasms.
Median enrollment 60 across the 14 interventional studies, 300 across the 4 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chinese University of Hong Kong is the lead sponsor of 1,457 studies on the registry; 477 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Stomach Neoplasms by Chinese University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04840056Chinese University of Hong KongPrediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis | 2026-12-01 |
| NCT07945756Chinese University of Hong KongDevelopment of a Gastric Cancer Screening Intervention for H. Pylori Carriers Based on the Health Belief Model | 2027-03-31 |
| NCT06926374Chinese University of Hong KongProspective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Stomach Neoplasms by Chinese University of Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gastric cancer (GC) remains a major global public health challenge. It often causes no obvious symptoms in the early stage, so most patients are diagnosed at an advanced stage. This highlights the importance of gastric cancer screening among high-risk populations to achieve early detection and improve survival outcomes. People infected with Helicobacter pylori (Hp) are at high risk of gastric cancer. Hp is one of the most common bacterial infections worldwide. It initiates carcinogenesis by triggering chronic atrophic gastritis and intestinal metaplasia, known as the Correa cascade. However, the acceptance of gastric cancer screening among Hp-infected individuals is still unsatisfactory. To our knowledge, there are few theory-based interventions designed to help Hp-infected people make decisions about gastric cancer screening and increase screening uptake. Therefore, based on our previous systematic review, this study aims to develop a health promotion program to improve gastric cancer screening participation among Hp-infected individuals in mainland China. Participants in the intervention group will receive a comprehensive health promotion program, including a 30-minute health education session. They will receive a 15-minute telephone follow-up with gastric cancer screening information in week 2, and additional 10-minute telephone follow-ups at weeks 2, 4, and 6 to help participants identify and overcome barriers to gastric cancer screening. Participants in the control group will receive routine care. Data on gastric cancer screening participation will be collected at the end of the intervention. Findings from this study will be valuable for gastric cancer prevention among people with Hp infection.
Participants in the intervention group will receive the following multi-session health promotion intervention. The details are as follows.
Screening benefit construction (30 min). In the first week, education will be delivered through face-to-face for the following information:
(1) Hp infection and increased gastric cancer risk; (2) gastric cancer screening recommendations regarding eligibility, available screening tests, and recommended screening intervals; (3) pros/advantages of undergoing gastric cancer screening; (4) cons/disadvantages or uncertainties of undergoing gastric cancer screening; (5) implications of positive screening results; and (6) health costs and service information. The educational material will be presented in a self-made manual, which will be explained and distributed to each participant.
Screening barrier navigation (15 min). It will be conducted in the second week by telephone. The nurse counsellor will help participants resolve individual barriers related to gastric cancer screening. The tailored content includes:
(1) Q\&A about gastroscopy screening; (2) gastroscopy appointment procedure; (3) hospital and transportation information; (4) medical insurance consultation; (5) precautions for the examination.
Screening self-efficacy reinforcement (10 min each). At the fourth and sixth weeks, the nurse counsellor will work with participants through a telephone-based way (with WeChat as an auxiliary tool) to strengthen confidence in completing gastric cancer screening, in which participants will: (1) track the progress of screening arrangements; (2) receive home health guidance while waiting for the screening examination.
Participants in the control group will receive routine health care for Hp infection without this theory-based gastric cancer screening promotion program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Previously diagnosed with gastric cancer or other advanced malignant tumors. 2. Cognitive impairment, severe hepatic or renal insufficiency, psychiatric disorders, or severe physical illness that prevents cooperation with the interview.
3. Pregnant or breastfeeding women.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Provide education, tailored information, barrier counseling, and decision support regarding gastric cancer screening for Helicobacter pylori-infected individuals.
Other: Health Belief Model-based screening promotion intervention
Usual care provided by the hospital, including one-page written education material on gastroscopy.
Other: Usual Care
Provide health education, tailored information, barrier counseling and follow-up regarding gastric cancer screening for Helicobacter pylori-infected individuals.
Usual care provided by the hospital, including one-page written education material on gastroscopy.
Gastric cancer screening intention
Participants' behavioral tendency and psychological readiness to actively seek and undergo gastroscopy within the next 5 years.
Time frame: Immediately and 6 weeks after intervention
Gastroscopy completion rate
An objective outcome is defined as the number of participants who complete gastroscopy after intervention. The gastroscopy completion rates among Helicobacter pylori-infected participants in the two groups will be compared, serving as the key quantitative indicator to evaluate whether the intervention improves actual screening behavior.
Time frame: 6 weeks after intervention
Gastric cancer screening knowledge score
Assessed with knowledge items from Huang et al. (2022). The scale measures participants' knowledge of gastric cancer risk factors and warning symptoms, consisting of 24 items on risk factors and 14 items on warning symptoms.
Time frame: Immediately and 6 weeks after intervention
Total score of the Health Belief Model (HBM) questionnaire for gastric cancer screening
This subscale was developed based on the five-dimensional HBM framework proposed by Becker (1974), including perceived susceptibility to gastric cancer (3 items), perceived severity (3 items), perceived benefits of gastric cancer screening (2 items), perceived barriers to screening (5 items), and cues to action (3 items). The total score of the five dimensions is calculated.
Time frame: Immediately and 6 weeks after intervention
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
Of 357 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 66. This study's planned 4 months is below that.
Counting every sponsor, half of 368 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →